Retinal Diseases
Conditions
Brief summary
Assess changes in the corneal cell count using Specular Microscopy following tretments with Anti-VEGF injections
Detailed description
Patients with active Wet AMD often receive intraocular Anti-VEGF injections such as Macugen, Lucentis and Avastin on a monthly basis for an extended period of time. While these medications are very effective at controlling the Choroidal Neovascularization associated with this disease, the impact of monthly intravigtreal Anti-VEGF injections on the viability of corneal endothelial cells has yet to be fully characterized. The availability of CESM as a diagnostic test that can be performed quickly and painlessly in the clinic offers a method of tracking corneal endothelial cell count in this patient population.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Wet Age-related Macular Degeneration * Receiving monthly intraocular injections of Anti-VEGF medication for at least 3 months * Age greater than 50 years of age
Exclusion criteria
* experiences adverse events
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Specular Photomicrographic Assessment of the Effect of Anti-VEGF Intravitreal injections on corneal thickness and endothelial cell density and morphology | Baseline, Month 6 and Month 12 | Changes in corneal endothelial cell density and corneal thickness measured by changes in pachymetry and corneal cell count. |
Countries
United States